MLD attending CCD and CCNA in October 2019

Written By Shawn Ritchie

Dr. Shawn Ritchie and Dr. Tara Smith will be attending the Canadian Conference on Dementia (CCD) and Canadian Consortium on Neurodengeneration in Aging (CCNA) to meet with collaborators regarding its first-in-class plasmalogen-directed therapy for Alzheimer’s Disease.

Shawn Ritchie
Previous

MLD's Plasmalogen Drug PPI-1040 for RCDP receives FDA Orphan Drug Designation (ODD)
Next

Dr. Tara Smith in Alabama for Rhizokids Conference